Provided by Tiger Trade Technology Pte. Ltd.

Arbutus Biopharma

4.29
-0.1600-3.60%
Post-market: 4.370.0800+1.86%19:43 EDT
Volume:1.38M
Turnover:6.01M
Market Cap:838.60M
PE:-24.54
High:4.55
Open:4.42
Low:4.28
Close:4.45
52wk High:5.10
52wk Low:2.71
Shares:195.48M
Float Shares:128.00M
Volume Ratio:0.40
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1748
EPS(LYR):-0.1748
ROE:-38.52%
ROA:-14.94%
PB:10.95
PE(LYR):-24.54

Loading ...

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

TIPRANKS
·
Feb 03

Moderna reverses lower after court issues memo in patent fight with Arbutus

TIPRANKS
·
Feb 03

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:38 PM

Reuters
·
Feb 03

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 21

European Patent Office ruling ‘clear win’ for Moderna, says Citi

TIPRANKS
·
Jan 20

Arbutus says European patent revoked by European Patent Office

TIPRANKS
·
Jan 20

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires Live
·
Jan 17

Top Midday Decliners

MT Newswires Live
·
Jan 17

Arbutus Biopharma Down Over 14%, on Pace for Largest Percent Decrease Since July 2020 -- Data Talk

Dow Jones
·
Jan 17

BRIEF-Arbutus Biopharma Corp - EPO Revokes Arbutus Biopharma's European Patent EP 2279254 - SEC Filing

Reuters
·
Jan 16

Arbutus Biopharma Corp: Co Disagrees With Outcome, Plans to File Petition for Review by Enlarged Board of Appeal of Epo

THOMSON REUTERS
·
Jan 16

Arbutus Biopharma Corp - Epo Revokes Arbutus Biopharma's European Patent Ep 2279254 - SEC Filing

THOMSON REUTERS
·
Jan 16

European Patent Office Revokes Arbutus Biopharma Patent Amid Ongoing Litigation

Reuters
·
Jan 16

Trevi Therapeutics Names David Hastings CFO

MT Newswires Live
·
Dec 04, 2025

Arbutus Biopharma Q3 Revenue USD 500 Thousand

Reuters
·
Nov 20, 2025

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 15, 2025

Arbutus Biopharma Q3 revenue and net loss miss analyst estimates

Reuters
·
Nov 13, 2025

Earnings Flash (ABUS) Arbutus Biopharma Posts Q3 Loss $0.04 a Share, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
Nov 13, 2025

Arbutus Biopharma Unveils Progress Toward Functional Cure for Chronic Hepatitis B

Reuters
·
Nov 13, 2025

Arbutus Biopharma reports $93.7 million in cash and marketable securities in Q3 2025

Reuters
·
Nov 13, 2025